2016-04-25 15:38:59 UTC

2016 Freston Conference: A Look at Session One

April 26, 2016

Learn what to expect at the first session of the August conference, which focuses on intestinal metaplasia.

Faculty from the upcoming 2016 James W. Freston Conference, which takes place Aug. 19 through 21 in Chicago, IL, are excited to provide more details about the upcoming conference. Over the next few weeks, we’ll highlight sessions from the conference and provide you with insight on what you can expect to be addressed. This week, we've outlined highlights from the first session.

Intestinal Metaplasia in the Esophagus and Stomach: Clinical and Historical Issues
The 2016 conference kicks things off by examining key clinical and histological features of intestinal metaplasia. Specifically, attendees will be able to:

  • Get clarification on the histological and biochemical differences between intestinal metaplasia in the esophagus and stomach.
  • Outline the risk of cancer for cardiac mucosa.
  • Determine if cardiac mucosa is metaplastic.

Be sure to check the May 5 issue of AGA eDigest and the AGA website for details on session two. To view the program in its entirety, visit the conference Web page.

More on Continuing Education

Final days to save on AGA Postgraduate Course

April 10, 2018

Early bird deadline is April 18 – last chance to save $75.

Overview of the Regulatory Framework and FDA’s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US

April 3, 2018

In this on-demand webinar, Sue Lim, MD provides an overview of the background, terminology and general requirements for biosimilar and interchangeable product applications.

The Development and Approval of Inflectra, a Biosimilar to Remicade: Case Presentation

April 3, 2018

In this on-demand webinar, Sue Lim, MD of the FDA provides a general review of the requirements for a biosimilar 351(k) application and discusses the approval process for Inflectra.